University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Tirzepatide and semaglutide offer long-term health benefits but are not cost-effective, according to a study publi ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Patients taking compounded weight loss drugs from online pharmacies share what it's like — and they couldn't go the ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Results indicate that tirzepatide and semaglutide provide substantial health benefits, including reductions in obesity, diabetes, and cardiovascular disease cases. However, high treatment costs ...

USA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.